Protext Mobility Unveils Corporate Platform and Venezuela LOI, Signaling Biotech-Pharma-Digital Infrastructure Ambitions
核心洞察
Protext Mobility Inc. (搜索) (OTCID: TXTM) launched a new corporate website and investor relations platform to reflect its evolution into biotechnology, pharmaceutical infrastructure, and digital systems.
The company is advancing proprietary live plant extraction, nanotechnology-enhanced formulations, and active pharmaceutical ingredient (API) development alongside digital asset and tokenization technologies.
President and Chairman Dr. Jamaloodeen executed a Letter of Intent with the Government of Venezuela during Venezuela Tech Week 2026, targeting collaborative opportunities in biotechnology and pharmaceutical infrastructure.
FORT LAUDERDALE, Fla., June 12, 2026 — Protext Mobility Inc. (搜索) (OTCID: TXTM) has unveiled a new corporate website and investor relations platform, marking what leadership describes as "the beginning of the next chapter" for the company as it positions itself at the convergence of biology, pharmaceutical science, and digital finance.
The company, which operates as a subsidiary of RAMMD Acquisitions LLC (搜索), is focused on engineering next-generation biological, pharmaceutical, and digital infrastructure systems through advanced biotechnology, proprietary live plant extraction science, active pharmaceutical ingredient (API) development, institutional technology platforms, and emerging digital infrastructure solutions.
"Our objective is straightforward: to engineer scalable infrastructure systems capable of bridging biological production, pharmaceutical-grade outputs, and next-generation digital capital markets," the company stated in its announcement.
Strategic Initiatives Spanning Biotechnology and Digital Finance
Protext Mobility's strategic initiatives encompass a broad portfolio that includes advanced API infrastructure, proprietary live plant extraction technologies, nanotechnology-enhanced processing and delivery systems, biotechnology infrastructure platforms, pharmaceutical formulation and processing systems, and agricultural production infrastructure.
On the digital side, the company is pursuing institutional financial frameworks, real-world asset (RWA) infrastructure, global digital liquidity systems, digital interoperability frameworks, asset verification and tokenization technologies, and emerging digital asset infrastructure.
"Through our vertically integrated approach, we continue developing systems intended to transform biological inputs into pharmaceutical-grade outputs while establishing the digital and institutional frameworks required for future scalability," the company noted.
The broader ecosystem has been developed through years of advancement across biotechnology research, agricultural infrastructure, pharmaceutical science, molecular preservation technologies, institutional financial positioning, and international strategic relationships.
Venezuela Tech Week 2026 and Government Letter of Intent
A significant development underscoring the company's international ambitions came through the participation of President and Chairman Dr. Jamaloodeen at the II Congreso Internacional de Emprendedores – Venezuela Tech Week 2026, held from May 11 through May 14, 2026, at the Parque Simón Bolívar Convention Center in La Carlota, Caracas, Venezuela.
The event brought together more than 500 international delegates representing over 50 countries, focusing on the transition toward a diversified, innovative, and sovereign economic model. During the congress, Dr. Jamaloodeen engaged with senior government officials, international business leaders, technology innovators, and institutional stakeholders.
Of particular significance, Dr. Jamaloodeen concluded the visit having successfully executed a Letter of Intent with the Government of the Bolivarian Republic of Venezuela. Management believes this engagement represents "an important step toward establishing future collaborative opportunities relating to biotechnology infrastructure, agricultural development, pharmaceutical initiatives, scientific innovation, and broader infrastructure deployment initiatives."
The company views its participation at this internationally attended forum as "recognition of the years of work invested in developing the scientific, agricultural, pharmaceutical, technological, and institutional foundations" that support its long-term growth strategy.
Leadership and Governance
CEO Mr. Dylon Du Plooy acknowledged the role of Dr. Jamaloodeen, stating that he "has played a central role in the development of the broader ecosystem that underpins the Company's strategic direction." Through years of advancement across agricultural infrastructure, biotechnology research, cultivation systems, molecular preservation technologies, institutional relationships, and international business development, Dr. Jamaloodeen has helped establish many of the foundational assets and strategic pathways now supporting Protext Mobility's future growth initiatives.
The company also acknowledged the dedication of its shareholders, noting that many "have remained committed throughout one of the most challenging periods in the Company's history."
Path Toward Exchange Uplisting
Protext Mobility outlined several milestones on its path toward exchange uplisting, including but not limited to 2024/2025 IFRS audited financials, proper price discovery valuations, the addition of a new advisory board member — a 20-year career diplomat who served as co-signatory to Dr. Jamaloodeen's LOI — as well as Main net and Broadridge investor awareness services.
"The launch of our new corporate website is not the destination. It is the beginning of the next chapter," the company stated, adding that it believes Protext Mobility is "uniquely positioned to participate in the future convergence of biotechnology, pharmaceutical infrastructure, and digital financial systems."
The company's long-term objective is to help bridge biological production systems with next-generation pharmaceutical and digital financial infrastructure by developing scalable pathways between real-world biological assets and global capital markets.